|
|
 |
DENTAL SCIENCE - REVIEW ARTICLE |
|
Year : 2014 | Volume
: 6
| Issue : 5 | Page : 6-8 |
|
|
Theranostics: A treasured tailor for tomorrow
S Jeelani1, RC Jagat Reddy2, Thangadurai Maheswaran3, GS Asokan4, A Dany5, B Anand6
1 Department of Oral Medicine and Radiology, Indira Gandhi Institute of Dental Sciences, Puducherry, India 2 Department of Oral Medicine and Radiology, Chettinad Dental College and Research Institute, Kelambakkam, Chennai, Tamil Nadu, India 3 Department of Oral Pathology, Vivekanandha Dental College for Women, Tiruchengode, Namakkal, Tamil Nadu, India 4 Department of Oral Medicine and Radiology, Tagore Dental College and Hospital, Chennai, Tamil Nadu, India 5 Department of Oral Medicine and Radiology, Sri Aurobindo College of Dentistry, Indore, Madhya Pradesh, India 6 Department of Oral Medicine and Radiology, Ragas Dental College and Hospital, Chennai, Tamil Nadu, India
Date of Submission | 30-Mar-2014 |
Date of Decision | 30-Mar-2014 |
Date of Acceptance | 09-Apr-2014 |
Date of Web Publication | 25-Jul-2014 |
Correspondence Address: Dr. S Jeelani Department of Oral Medicine and Radiology, Indira Gandhi Institute of Dental Sciences, Puducherry India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0975-7406.137249
Abstract | | |
Emerging as a targeted, safe, and efficient pharmacotherapy is the approach of theranostics, which focuses on patient-centered care. It is a combination of diagnosis and therapeutics. It provides a transition from conventional medicine to personalized medicine. It deals with the custom made treatment plan based on uniqueness of every individual thus resulting in right drug for the right patient at the right time. Genetics plays a significant role in theranostics. Theranostics provides a cost-effective specific successful treatment protocol. Pharmacogenetics, proteomics and biomarker profiling forms the backbone of theranostics. The role of theranostics is interestingly appreciated at multi levels with special consideration in oncology wherein nano formulations in the form of liposomes, dendrimers, polymeric nanoparticles, metallic nanoparticles, quantum dots and carbon nanotubes play a very important role. Thus, theranostics is a holistic transition from trial and error medicine to predictive, preventive and personalized medicine leading to improved quality care of pharmacotherapy. Keywords: Diagnosis, personalized medicine, theranostics, therapy
How to cite this article: Jeelani S, Jagat Reddy R C, Maheswaran T, Asokan G S, Dany A, Anand B. Theranostics: A treasured tailor for tomorrow. J Pharm Bioall Sci 2014;6, Suppl S1:6-8 |
How to cite this URL: Jeelani S, Jagat Reddy R C, Maheswaran T, Asokan G S, Dany A, Anand B. Theranostics: A treasured tailor for tomorrow. J Pharm Bioall Sci [serial online] 2014 [cited 2022 Aug 17];6, Suppl S1:6-8. Available from: https://www.jpbsonline.org/text.asp?2014/6/5/6/137249 |
Advances in science have always been an inseparable part of human contribution to the welfare of mankind. Traditional medicine has relied upon rationale history taking, relevant clinical examination for arriving at the cause of the problem - diagnosis and planning of appropriate management initially, which was with herbs, and which later gradually progressed to chemical products of plants and various other sources resulting in diverse medical modalities. The arrival of diagnosis and treatment was a reactive approach, which completely depended upon and focused on the individual patient's clinical signs and symptoms, past medical history, personal history, family history, and results of investigations from laboratory and occasionally imaging to diagnose illnesses and planning the relevant treatment modalities with common platform being medical management with drugs.
Patient-centered care has always been the priority and predominant basis of treating patients with drugs and more important a transition from universal medicine that is, "one medicine fits all" practice to personalized medicine has emerged as a revolution to include the unique approach for custom-made drug therapy based on interpersonal variation in drug response. This has to the exploration of an amazing platform called theranostics, which is an intimate connection of diagnosis and therapeutics that could provide treatment protocols, which are more specific to individuals and therefore, more likely to provide improved prognoses thus drawing diagnosis and therapy closer. The objective is to render safe and more targeted efficient pharmacotherapy by offering individual patients the "right" drug at the "right" dose in the form of theranostics as part of personalized medicine. [1],[2],[3],[4]
Theranostics - portmanteau of therapeutics and diagnostics Portmanteau means a combination of two (or more) words into one new word. Theranostics combines therapy and diagnostics. [5] The pioneer of the term theranostics is attributed to John Funkhouser. The term "theranostics" was coined to explain developments in science to establish more specific and individualized therapies for various pathologies, and to bring about a union of diagnostic and therapeutic applications into a single agent thus leading to a promising therapeutic paradigm involving diagnosis, drug delivery and monitoring of treatment response. [6]
Theranostics is a proposed process of diagnostic therapy for individual patients - to test them for possible reaction to taking a new medication and to tailor a treatment for them based on the test results.
Of utmost importance is that theranostics plays a significant role in economic aspect resulting in cost-effective treatment plans and highly efficient and specific medicine protocols, serving as a guidance in preclinical drug development or clinical trial eligibility to obtain positive results.
Genetic information forms a key part in theranostics and it has been contributed by Human genome project, which emphasizes on variations in genetics and expected risk for many of the common diseases. Interestingly, this has led to the growth of fields such as pharmacogenetics and proteomics. [7]
Pharmacogenetics | |  |
Pharmacogenetics is the science that studies about the individual variations in DNA sequences and responses to treatment interventions by biomarker. This genotyping approach helps in tailoring drug therapy with advantages such as reduction in time and cost and increase in success rates. The field of pharmacogenomics extends to cover variations in RNA and proteins also that may have significance in treatment decisions. [8]
Proteomics | |  |
It is the science that deals with comprehensive analysis and characterization of all of the proteins and protein isoforms encoded by the human genome. Proteomics also plays a very vital role in tailoring therapy and have therapeutic implications because proteins play an important role in the physiological aspect of the cell when compared to the genes which is the storehouse of information. [9]
Biomarker Profiling | |  |
Theranostics tailors optimized therapies based on biomarker profile of each individual patient's specimen reducing side-effects and increasing tissue bio availability thus reducing treatment costs and improving response to treatment. Today's biomarker is tomorrow's theranostics. [10]
Challenges in Theranostics | |  |
The fundamental principle of theranostics has been followed since decades, with the utilization of radioiodine to diagnose (image) and manage cancers of thyroid gland which dates back to 1940. Since its inception until date, theranostics has been fostering unremarkable tailored and targeted therapy.
In the context of pharmacotherapy, the fundamental aspect of individual absorption distribution metabolism excretion is to understood with regards to the complex interactions and detailed characterization, especially focusing on the functional variations genetically also including population variations. Furthermore interestingly, epigenetic variations and the impact of environmental factors including the circadian rhythms on an individual's response to drugs needs to be assessed specific to each individual.
Apart from the above variations educating the health care provider, payor, regulator, and the patient also is mandatory. Theranostics has extended impact on patients in that more than individual centric care, guaranteed outcomes expected by patients seem to pose an alarming aspect of theranostics.
Due to existing less targeted and tailored pharmacotherapy, the resulting loss in 40% of ineffective treatment has resulted in loss in overall economy of the pharmacological market accounting to $400 billion out of total global pharmaceutical market $825 billion. Our country accounts to 20% of global population and involves 2% of global pharmaceutical market, especially with respect to generic drugs. Every year after conducting clinical trials, approval by the Central Drugs Standard Control Organization has considerably decreased since 2009.
The most common reason for failure and avoidable deaths, including expensive hospitalization has been found to be side effects associated with less targeted nonspecific therapy contrary to theranostics based management. Furthermore age, and gender, diet, lifestyle of a patient including the intestinal microflora plays a significant role in patient's response to a drug. [11]
Theranostics in Oncology | |  |
In contrast to normal cells, cancer cells break the harmony of normal check points and divide and live forever by maintaining their telomeres (a region of repetitive DNA at the end of a chromosome from deterioration thus leading to uncontrolled growth and spread).
Currently, employed techniques in diagnosis are limited by lack of specificity and treatment associated with systemic toxicity. Current treatment techniques for cancer include surgery, radiotherapy, chemotherapy, hyperthermia, immunotherapy, hormone therapy, stem cell therapy, and combinations of above.
Opening new vistas in cancer management in three dimensions - diagnosis treatment and monitoring the response is the application of theranostics, especially with the support of nanotechnology. [12]
Liposomes, dendrimers, polymeric nanoparticles, metallic nanoparticles, quantum dots and carbon nanotubes are examples of nano formulations that can be used as mutifunctional platforms for cancer theranostics. Liposomes are concentric closed bilayer membranes of water insoluble polar lipids that can be used to encapsulate biomolecules and drugs for targeted delivery, while protecting their bioactivity. Members of the fullerene structural class, carbon based are carbon nano tubes. Nano tubes are a sheet of graphite rolled into a cylinder. They are composed of carbon atoms arranged in hexagonal networks that are approximately 1 nm in diameter and 1-100 μm in length. The generation of them takes place by the optical excitation of plasmonic nanoparticles with short pulses of laser. They are used as localized nano bombs to destroy cancer cells. Quantum dots are semi-conductor nano crystals made of cadmium selenide that range from 2 to 10 nm in diameter, which glow when exposed to ultraviolet light and are useful in the detection of cancer in very incipient stages and preferentially killing them. Thus theranostics opens new avenues from point of diagnostic care and allows for holistic patient management approaches. [13],[14],[15],[16],[17]
Conclusion | |  |
A seamless and interesting integration of multiple imaging and treatment technologies within a single nano particle is required to tackle pathologies. Nanorobots approximately the dimension of bacteria probably 1 day may roam human's bodies tracking out organisms and repairing damaged body tissues. [18]
In the broader sense, theranostics is a proposed diagnostic methodology for personalizing treatment intervention (diagnostic therapy for individual patients).
Theranostics paves a way for the holistic transition from "trial and error" medicine to personalized medicine. Personalized medicine or PM is an interesting field that plans with the customization in caring for health - with relevant medical decisions, rationale practices, and/or various products being tailored to the specific patient.
Contradictory to one decision suits all practice, personalized medicine has revolutionized as a genuine interventional approach for custom-made drug regimen based on variations between patients with respect to drug response rendering increased safety and improved efficiency thus offering the right drug with right dose to the right patient at the right time. This is achieved by properly identifying and appropriately selecting patients with a specific molecular phenotype indicative of positive response to treatment. [19]
Thus, theranostics approach can be considered as "P4 medicine," that is predictive, preventive, personalized, and participatory. This field promises to increase the quality of clinical care and treatments and will ultimately save costs thus helps to identify the right drug for the right patient at the right time. [20]
References | |  |
1. | Mitri Z, Esmerian MO, Simaan JA, Sabra R, Zgheib NK. Pharmacogenetics and personalized medicine: The future for drug prescribing. J Med Liban 2010;58:101-4.  |
2. | Ruano G. Quo vadis personalized medicine? Pers Med 2004;1:1-7.  |
3. | Landais P, Méresse V, Ghislain JC. Evaluation and validation of diagnostic tests for guiding therapeutic decisions. Therapie 2009;64:187-201.  |
4. | Lin W. Molecular diagnostic renovates drug development: overcoming challenges of co-development of theranostics. Trends Bio/Pharm Ind 2007;4:26-8.  |
5. | Pene F, Courtine E, Cariou A, Mira JP. Toward theragnostics. Crit Care Med 2009;37:S50-8.  |
6. | Idée JM, Louguet S, Ballet S, Corot C. Theranostics and contrast-agents for medical imaging: A pharmaceutical company viewpoint. Quant Imaging Med Surg 2013;3:292-7.  |
7. | Shastry BS. Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J 2006;6:16-21.  |
8. | Lanfear DE, McLeod HL. Pharmacogenetics: Using DNA to optimize drug therapy. Am Fam Physician 2007;76:1179-82.  |
9. | Pirazzoli A, Recchia G. Pharmacogenetics and pharmacogenomics: Are they still promising? Pharmacol Res 2004;49:357-61.  |
10. | Kim TH, Lee S, Chen X. Nanotheranostics for personalized medicine. Expert Rev Mol Diagn 2013;13:257-69.  |
11. | Nimita L. Pharmacogenomics, theranostics and personalized medicine-The complexities of clinical trials: challenges in the developing world. Appl Transl Genomics 2013;2:17-21.  |
12. | Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751-60.  |
13. | Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev 2010;62:1064-79.  |
14. | Fernandez-Fernandez A, Manchanda R, McGoron AJ. Theranostic applications of nanomaterials in cancer: Drug delivery, image-guided therapy, and multifunctional platforms. Appl Biochem Biotechnol 2011;165:1628-51.  |
15. | Sumer B, Gao J. Theranostic nanomedicine for cancer. Nanomedicine (Lond) 2008;3:137-40.  |
16. | Chan WC, Maxwell DJ, Gao X, Bailey RE, Han M, Nie S. Luminescent quantum dots for multiplexed biological detection and imaging. Curr Opin Biotechnol 2002;13:40-6.  |
17. | Lapotko D. Plasmonic nanobubbles as tunable cellular probes for cancer theranostics. Cancers (Basel) 2011;3:802-40.  |
18. | Bhattarai N, Bhattarai SR. Theranostic nanoparticles: A recent breakthrough in nanotechnology. J Nanomed Nanotechol 2012;3:e114.  |
19. | Chan IS, Ginsburg GS. Personalized medicine: Progress and promise. Annu Rev Genomics Hum Genet 2011;12:217-44.  |
20. | Sairamesh J, Michael R. An economic perspective on personalized medicine. Hugo J 2013;7:1.  |
This article has been cited by | 1 |
Recent Development in Metallic Nanoparticles for Breast Cancer Therapy and Diagnosis |
|
| Md Abdus Subhan, Mohammed Muzibur Rahman | | The Chemical Record. 2022; | | [Pubmed] | [DOI] | | 2 |
Enzyme-mediated intratumoral self-assembly of nanotheranostics for enhanced imaging and tumor therapy |
|
| Yue Yuan, Jeff W. M. Bulte | | WIREs Nanomedicine and Nanobiotechnology. 2022; | | [Pubmed] | [DOI] | | 3 |
A comprehensive update of micro- and nanobubbles as theranostics in oncology |
|
| Ashok David Jose, Zimei Wu, Sachin Sunil Thakur | | European Journal of Pharmaceutics and Biopharmaceutics. 2022; 172: 123 | | [Pubmed] | [DOI] | | 4 |
Current trends in theranostic nanomedicines |
|
| Meghanath B. Shete, Tulshidas S. Patil, Ashwini S. Deshpande, Gaurav Saraogi, Nupur Vasdev, Mrudul Deshpande, Kuldeep Rajpoot, Rakesh Kumar Tekade | | Journal of Drug Delivery Science and Technology. 2022; 71: 103280 | | [Pubmed] | [DOI] | | 5 |
A Second Near-Infrared Ru(II) Polypyridyl Complex for Synergistic Chemo-Photothermal Therapy |
|
| Yishen Liu, Qianqian Li, Meijia Gu, Disheng Lu, Xiaoxing Xiong, Zhiyun Zhang, Yanna Pan, Yuqin Liao, Qihang Ding, Wanxia Gong, Dean Shuailin Chen, Mengting Guan, Junzhu Wu, Zhiquan Tian, Hai Deng, Lijuan Gu, Xuechuan Hong, Yuling Xiao | | Journal of Medicinal Chemistry. 2022; | | [Pubmed] | [DOI] | | 6 |
A Modified Oxazolone Dye Dedicated to Spectroscopy and Optoelectronics |
|
| Adam Szukalski, Przemyslaw Krawczyk, Bouchta Sahraoui, Faustyna Rosinska, Beata Jedrzejewska | | The Journal of Organic Chemistry. 2022; | | [Pubmed] | [DOI] | | 7 |
Multifunctional Oxazolone Derivative as an Optical Amplifier, Generator, and Modulator |
|
| Adam Szukalski, Przemyslaw Krawczyk, Bouchta Sahraoui, Beata Jedrzejewska | | The Journal of Physical Chemistry B. 2022; | | [Pubmed] | [DOI] | | 8 |
Advances in FePt-involved nano-system design and application for bioeffect and biosafety |
|
| Zunfu Hu, Qiulian Wei, Huimin Zhang, Weina Tang, Yunkai Kou, Yunqiang Sun, Zhichao Dai, Xiuwen Zheng | | Journal of Materials Chemistry B. 2022; | | [Pubmed] | [DOI] | | 9 |
Smart contact lenses and anterior chamber electronic implants: prospects of application in ophthalmology |
|
| D. M. Shamaev, V. V. Zayats, E. N. Iomdina, P. V. Luzhnov, O. I. Nikitin | | Russian Ophthalmological Journal. 2022; 15(2): 177 | | [Pubmed] | [DOI] | | 10 |
Micro/Nanosystems for Magnetic Targeted Delivery of Bioagents |
|
| Francesca Garello, Yulia Svenskaya, Bogdan Parakhonskiy, Miriam Filippi | | Pharmaceutics. 2022; 14(6): 1132 | | [Pubmed] | [DOI] | | 11 |
Nanotheranostics: A powerful next-generation solution to tackle hepatocellular carcinoma |
|
| Rusdina Bte Ladju, Zulvikar Syambani Ulhaq, Gita Vita Soraya | | World Journal of Gastroenterology. 2022; 28(2): 176 | | [Pubmed] | [DOI] | | 12 |
Advances in Non-Animal Testing Approaches towards Accelerated Clinical Translation of Novel Nanotheranostic Therapeutics for Central Nervous System Disorders |
|
| Mark J. Lynch, Oliviero L. Gobbo | | Nanomaterials. 2021; 11(10): 2632 | | [Pubmed] | [DOI] | | 13 |
Nanomaterials as Novel Cardiovascular Theranostics |
|
| Rajasekharreddy Pala, Subhaswaraj Pattnaik, Siddhardha Busi, Surya M. Nauli | | Pharmaceutics. 2021; 13(3): 348 | | [Pubmed] | [DOI] | | 14 |
Current State of Breast Cancer Diagnosis, Treatment, and Theranostics |
|
| Arya Bhushan, Andrea Gonsalves, Jyothi U. Menon | | Pharmaceutics. 2021; 13(5): 723 | | [Pubmed] | [DOI] | | 15 |
Photo-triggered Theranostic Nanoparticles in Cancer Therapy |
|
| Celine DG. Abueva | | Medical Lasers. 2021; 10(1): 7 | | [Pubmed] | [DOI] | | 16 |
Secondary Radiation in Ion Therapy and Theranostics: A Review |
|
| Maitreyee Nandy | | Frontiers in Physics. 2021; 8 | | [Pubmed] | [DOI] | | 17 |
The Need for the Establishment of Biomedical Engineering as an Academic and Professional Discipline in the Philippines—A Quantitative Argument |
|
| Jamie Ledesma Fermin, Myles Joshua Toledo Tan | | IEEE Access. 2021; 9: 3097 | | [Pubmed] | [DOI] | | 18 |
Review of the Mechanism of Nanocarriers and Technological Developments in the Field of Nanoparticles for Applications in Cancer Theragnostics |
|
| Nehil Shreyash, Muskan Sonker, Sushant Bajpai, Saurabh Kr Tiwary | | ACS Applied Bio Materials. 2021; 4(3): 2307 | | [Pubmed] | [DOI] | | 19 |
The use of radioactive substances in medicine — history and development prospects |
|
| M. S. Sheremeta, A. A. Trukhin, M. O. Korchagina | | Problems of Endocrinology. 2021; 67(6): 59 | | [Pubmed] | [DOI] | | 20 |
Harnessing the Combined Potential of Cancer Immunotherapy and Nanomedicine: A New Paradigm in Cancer Treatment |
|
| Cherylette Anne Alexander, Yi Yan Yang | | Nanomedicine: Nanotechnology, Biology and Medicine. 2021; : 102492 | | [Pubmed] | [DOI] | | 21 |
Systematic identification of clinically relevant miRNAs for potential miRNA-based therapy in lung adenocarcinoma |
|
| Shu-Hsuan Liu, Kai-Wen Hsu, Yo-Liang Lai, Yu-Feng Lin, Fang-Hsin Chen, Pei-Hwa Peng, Li-Jie Lin, Heng-Hsiung Wu, Chia-Yang Li, Shu-Chi Wang, Min-Zu Wu, Yuh-Pyng Sher, Wei-Chung Cheng | | Molecular Therapy - Nucleic Acids. 2021; 25: 1 | | [Pubmed] | [DOI] | | 22 |
From cuvette to cells: How the central metal ion modulates the properties of phthalocyanines and porphyrazines as photosensitizers |
|
| Gabriel F.M. Pereira, Thiago T. Tasso | | Inorganica Chimica Acta. 2021; 519: 120271 | | [Pubmed] | [DOI] | | 23 |
BCLA CLEAR – Contact lens technologies of the future |
|
| Lyndon Jones, Alex Hui, Chau-Minh Phan, Michael L. Read, Dimitri Azar, John Buch, Joseph B. Ciolino, Shehzad A. Naroo, Brian Pall, Kathleen Romond, Padmaja Sankaridurg, Cristina M. Schnider, Louise Terry, Mark Willcox | | Contact Lens and Anterior Eye. 2021; 44(2): 398 | | [Pubmed] | [DOI] | | 24 |
PSMA Theranostics: A “Must Have” in Every Prostate Cancer Center. Illustration of Two Clinical Cases and Review of the Literature |
|
| Wojciech Cytawa, Philipp Hartrampf, Piotr Lass, Malte Kircher, Bülent Polat, Andreas K. Buck, Constantin Lapa | | Clinical Genitourinary Cancer. 2021; 19(4): e235 | | [Pubmed] | [DOI] | | 25 |
Electrohydrodynamic atomisation driven design and engineering of opportunistic particulate systems for applications in drug delivery, therapeutics and pharmaceutics |
|
| Amna Ali, Aliyah Zaman, Elshaimaa Sayed, David Evans, Stuart Morgan, Chris Samwell, John Hall, Muhammad Sohail Arshad, Neenu Singh, Omar Qutachi, Ming-Wei Chang, Zeeshan Ahmad | | Advanced Drug Delivery Reviews. 2021; 176: 113788 | | [Pubmed] | [DOI] | | 26 |
Application and Importance of Theranostics in the Diagnosis and Treatment of Cancer |
|
| Shareni Jeyamogan, Naveed Ahmed Khan, Ruqaiyyah Siddiqui | | Archives of Medical Research. 2021; 52(2): 131 | | [Pubmed] | [DOI] | | 27 |
Apoferritin and Dps as drug delivery vehicles: Some selected examples in oncology |
|
| Anchala I. Kuruppu, Lyudmila Turyanska, Tracey D. Bradshaw, Sivakumar Manickam, Bandula Prasanna Galhena, Priyani Paranagama, Ranil De Silva | | Biochimica et Biophysica Acta (BBA) - General Subjects. 2021; : 130067 | | [Pubmed] | [DOI] | | 28 |
Imaging, Identification and Inhibition of Microorganisms Using AIEgens |
|
| Harini A. Perera, Mingdi Yan | | Topics in Current Chemistry. 2021; 379(3) | | [Pubmed] | [DOI] | | 29 |
Advances in Biosensors and Diagnostic Technologies Using Nanostructures and Nanomaterials |
|
| E. Celeste Welch, Jessica M. Powell, Tobias B. Clevinger, Alexis E. Fairman, Anita Shukla | | Advanced Functional Materials. 2021; 31(44): 2104126 | | [Pubmed] | [DOI] | | 30 |
Artificial intelligence should be part of medical physics graduate program curriculum |
|
| Lei Xing, Steven Goetsch, Jing Cai | | Medical Physics. 2021; 48(4): 1457 | | [Pubmed] | [DOI] | | 31 |
Fabrication of gold nanohybrids modified with antibody and functional dendrimers for targeted photothermal theranostics |
|
| Herlan Setiawan, Eiji Yuba, Atsushi Harada, Ichio Aoki, Kenji Kono | | Nano Select. 2021; 2(4): 779 | | [Pubmed] | [DOI] | | 32 |
Smart Gold Nanostructures for Light Mediated Cancer Theranostics: Combining Optical Diagnostics with Photothermal Therapy |
|
| Tanveer A. Tabish, Priyanka Dey, Sara Mosca, Marzieh Salimi, Francesca Palombo, Pavel Matousek, Nicholas Stone | | Advanced Science. 2020; 7(15): 1903441 | | [Pubmed] | [DOI] | | 33 |
Building sophisticated sensors of extracellular cues that enable mammalian cells to work as “doctors” in the body |
|
| Ryosuke Kojima, Dominque Aubel, Martin Fussenegger | | Cellular and Molecular Life Sciences. 2020; 77(18): 3567 | | [Pubmed] | [DOI] | | 34 |
Biosensors in diagnosing COVID-19 and recent development |
|
| Soumyashree Behera, Geetanjali Rana, Subhadarshini Satapathy, Meenakshee Mohanty, Srimay Pradhan, Manasa Kumar Panda, Rina Ningthoujam, Budhindra Nath Hazarika, Yengkhom Disco Singh | | Sensors International. 2020; 1: 100054 | | [Pubmed] | [DOI] | | 35 |
Synthesis of Heterofunctional Polyester Dendrimers with Internal and External Functionalities as Versatile Multipurpose Platforms |
|
| Sandra García-Gallego, Patrik Stenström, Pablo Mesa-Antunez, Yuning Zhang, Michael Malkoch | | Biomacromolecules. 2020; 21(10): 4273 | | [Pubmed] | [DOI] | | 36 |
Neutron-activated theranostic radionuclides for nuclear medicine |
|
| Hun Yee Tan, Chai Hong Yeong, Yin How Wong, Molly McKenzie, Azahari Kasbollah, Mohamad Nazri Md. Shah, Alan Christopher Perkins | | Nuclear Medicine and Biology. 2020; 90-91: 55 | | [Pubmed] | [DOI] | | 37 |
Modulated Electrohyperthermia: A New Hope for Cancer Patients |
|
| Huda F. Alshaibi, Bashayr Al-shehri, Basmah Hassan, Raghad Al-zahrani, Taghreed Assiss, Ming Yi | | BioMed Research International. 2020; 2020: 1 | | [Pubmed] | [DOI] | | 38 |
Hollow silicon microneedle fabrication using advanced plasma etch technologies for applications in transdermal drug delivery |
|
| Chris J. W. Bolton, Olivia Howells, Gareth J. Blayney, Pey F. Eng, James C. Birchall, Benedetta Gualeni, Kerry Roberts, Huma Ashraf, Owen J. Guy | | Lab on a Chip. 2020; 20(15): 2788 | | [Pubmed] | [DOI] | | 39 |
Rational design of an “all-in-one” phototheranostic |
|
| Zi-Shu Yang, Yuhang Yao, Adam C. Sedgwick, Cuicui Li, Ye Xia, Yan Wang, Lei Kang, Hongmei Su, Bing-Wu Wang, Song Gao, Jonathan L. Sessler, Jun-Long Zhang | | Chemical Science. 2020; 11(31): 8204 | | [Pubmed] | [DOI] | | 40 |
Translating Biomarkers of Cholangiocarcinoma for Theranosis: A Systematic Review |
|
| Imeshi Wijetunga, Laura E. McVeigh, Antonia Charalambous, Agne Antanaviciute, Ian M. Carr, Amit Nair, K. Raj Prasad, Nicola Ingram, P. Louise Coletta | | Cancers. 2020; 12(10): 2817 | | [Pubmed] | [DOI] | | 41 |
Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy |
|
| Bijay Singh, Shicheng Yang, Apurva Krishna, Srinivas Sridhar | | Frontiers in Chemistry. 2020; 8 | | [Pubmed] | [DOI] | | 42 |
Clinical failure of nanoparticles in cancer: mimicking nature's solutions |
|
| Pablo Hernández-Camarero, Víctor Amezcua-Hernández, Gema Jiménez, María A García, Juan A Marchal, Macarena Perán | | Nanomedicine. 2020; 15(23): 2311 | | [Pubmed] | [DOI] | | 43 |
COVID-19: Perspectives for the management of dental care and education |
|
| Bruno César de Vasconcelos Gurgel, Samuel Batista Borges, Raul Elton Araújo Borges, Patrícia dos Santos Calderon | | Journal of Applied Oral Science. 2020; 28 | | [Pubmed] | [DOI] | | 44 |
Chapitre 6. Nanomédecine et médecine personnalisée : appréhender le sens et les défis de la personnalisation du soin à l’heure des technologies moléculaires |
|
| Mathieu Noury | | Journal international de bioéthique et d'éthique des sciences. 2019; Vol. 30(1): 133 | | [Pubmed] | [DOI] | | 45 |
Photophysical Properties of Novel Two-Photon Absorbing Dyes: Assessing Their Possible Use for Singlet Oxygen Generation |
|
| Ozlem Sengul, Marco Marazzi, Antonio Monari, Saron Catak | | The Journal of Physical Chemistry C. 2018; 122(28): 16315 | | [Pubmed] | [DOI] | | 46 |
Skin Cancer and Its Treatment: Novel Treatment Approaches with Emphasis on Nanotechnology |
|
| Kristjan Orthaber,Matevž Pristovnik,Kristijan Skok,Barbara Peric,Uroš Maver | | Journal of Nanomaterials. 2017; 2017: 1 | | [Pubmed] | [DOI] | | 47 |
First in vivo MRI study on theranostic dendrimersomes |
|
| Miriam Filippi,Valeria Catanzaro,Deyssy Patrucco,Mauro Botta,Lorenzo Tei,Enzo Terreno | | Journal of Controlled Release. 2017; | | [Pubmed] | [DOI] | | 48 |
Emerging proteomics biomarkers and prostate cancer burden in Africa |
|
| Henry A. Adeola, Jonathan M. Blackburn, Timothy R. Rebbeck, Luiz F. Zerbini | | Oncotarget. 2017; 8(23): 37991 | | [Pubmed] | [DOI] | | 49 |
Rapid Biosynthesis of Silver Nanoparticles Using Pepino (Solanum muricatum) Leaf Extract and Their Cytotoxicity on HeLa Cells |
|
| Mónica Gorbe,Ravishankar Bhat,Elena Aznar,Félix Sancenón,M. Marcos,F. Herraiz,Jaime Prohens,Abbaraju Venkataraman,Ramón Martínez-Máñez | | Materials. 2016; 9(5): 325 | | [Pubmed] | [DOI] | | 50 |
Toward a world of theranostic medication: Programming biological sentinel systems for therapeutic intervention |
|
| Ryosuke Kojima,Dominique Aubel,Martin Fussenegger | | Advanced Drug Delivery Reviews. 2016; | | [Pubmed] | [DOI] | | 51 |
Concise Review: Stem Cell Trials Using Companion Animal Disease Models |
|
| Andrew M. Hoffman,Steven W. Dow | | STEM CELLS. 2016; 34(7): 1709 | | [Pubmed] | [DOI] | | 52 |
Personalized Medicine Based on Theranostic Radioiodine Molecular Imaging for Differentiated Thyroid Cancer |
|
| Byeong-Cheol Ahn | | BioMed Research International. 2016; 2016: 1 | | [Pubmed] | [DOI] | | 53 |
Measuring pharmacogenetics in special groups: geriatrics |
|
| Davide Seripa,Francesco Panza,Julia Daragjati,Giulia Paroni,Alberto Pilotto | | Expert Opinion on Drug Metabolism & Toxicology. 2015; 11(7): 1073 | | [Pubmed] | [DOI] | | 54 |
Metal nanoparticles: a theranostic nanotool against cancer |
|
| Harshita Sharma,Pawan K. Mishra,Sushama Talegaonkar,Bhuvaneshwar Vaidya | | Drug Discovery Today. 2015; 20(9): 1143 | | [Pubmed] | [DOI] | | 55 |
Novel theranostic agents for next-generation personalized medicine: small molecules, nanoparticles, and engineered mammalian cells |
|
| Ryosuke Kojima,Dominique Aubel,Martin Fussenegger | | Current Opinion in Chemical Biology. 2015; 28: 29 | | [Pubmed] | [DOI] | |
|
 |
 |
|